Barclays analyst Matt Miksic maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on May 3 and set a price target of $55.00. The company’s shares closed last Friday at $44.72.
According to TipRanks, Miksic is a 5-star analyst with an average return of 7.0% and a 59.50% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Baxter International, and LivaNova.
In addition to Barclays, Tandem Diabetes Care also received a Buy from TD Cowen’s Josh Jennings in a report issued on May 3. However, on the same day, Robert W. Baird maintained a Hold rating on Tandem Diabetes Care (NASDAQ: TNDM).
Based on Tandem Diabetes Care’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $196.8 million and a GAAP net loss of $30 million. In comparison, last year the company earned a revenue of $220.5 million and had a GAAP net loss of $15.85 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care (TNDM) Company Description:
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
- Tandem Diabetes price target raised to $50 from $35 at Piper Sandler
- Tandem Diabetes price target raised to $50 from $45 at Wells Fargo
- Tandem Diabetes price target raised to $45 from $35 at TD Cowen
- Tandem Diabetes price target raised to $36 from $28 at Baird
- Tandem Diabetes sees Fy24 revenue $868M, consensus $845.5M
